From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada
Epoetin SEB uptake rates
Year 1
Year 2
Year 3
Year 4
Year 5
1%
4%
7%
11%
14%